Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Company Profile for MGI PHARMA, INC.


MGI MGI Mouse Genome Informatics
MGI Modular Gateway Interface
MGI McKinsey Global Institute
MGI Military Geographic Information
MGI Marine Geological Institute
MGI Policy on the Management of Government Information (Canada) 
 PHARMA, INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic.

Antonym: dec.
. is a biopharmaceutical company focused in oncology oncology /on·col·o·gy/ (ong-kol´ah-je) the sum of knowledge regarding tumors; the study of tumors.

on·col·o·gy
n.
 and acute care that acquires, researches, develops and commercializes proprietary products that address the unmet needs of patients. MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride palonosetron hydrochloride

Aloxi

Pharmacologic class: Selective serotonin subtype 3 (5-HT3) receptor antagonist

Therapeutic class: Antiemetic

Pregnancy risk category B

) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. . The Company directly markets its products in the U.S. and collaborates with partners to reach international markets. For more information about MGI PHARMA, please visit www.mgipharma.com.
Company:                MGI PHARMA, INC.

   Headquarters Address:   5775 West Old Shakopee Road
                           Suite 100
                           Bloomington, MN 55437

   Main Telephone:         952-346-4700

   Website:                www.mgipharma.com

   Ticker:                 MOGN(NASDAQ)

   Type of Organization:   Public

   Industry:               Health: Biotechnology

   Earnings Release Dates: 3rd Quarter: October 18, 2006
                           4th Quarter: February 7, 2007


   Key Executives:         President and CEO: Lonnie Moulder
                           Executive Vice President and CFO: Bill
                            Spengler

   Investor Relations
     Contact:              Jennifer Davis
     Phone:                212-332-4381
     Email:                ir@mgipharma.com
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Company overview
Geographic Code:1USA
Date:Sep 1, 2006
Words:154
Previous Article:Complete Analysis of Product Segments Collagen Based Biomaterials and Hyaluronic Acid Based Biomaterials under the Collagen and HA-Based Biomaterials...
Next Article:Currently, Australia Has Close To 2000 Certified Organic Producers, Processors and Retailers of Organic Food and Fiber Products Valued At $180...
Topics:



Related Articles
MGI PHARMA And Alpharma Enter into Promotion Agreement for Kadian in Cancer Pain.
MGI PHARMA Reports Third Quarter Financial Results.
MGI PHARMA to Acquire Guilford Pharmaceuticals.
MGI PHARMA and Guilford Pharmaceuticals Announce Expiration of the Hart-Scott-Rodino Waiting Period.
Approvable Letter Received from the FDA for Dacogen(TM) (Decitabine) Injection for the Treatment of MDS; Conference Call To Be Held At 5:15 PM ET...
MGI PHARMA Completes Acquisition of Guilford Pharmaceuticals.
MGI PHARMA Announces Commencement of Tender Offer for Guilford Pharmaceutical Notes Due 2008.
MGI PHARMA Announces Expiration of Tender Offer for Guilford Pharmaceuticals Notes Due 2008.
MGI PHARMA To Present at the 2006 UBS Global Specialty Pharmaceuticals Conference.
MGI PHARMA Appoints William F. Spengler As CFO.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles